drugset / Trial / NCT00903006
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Phase 1/2
Terminated
11 enrolled
M.D. Anderson Cancer Center
Bristol-Myers Squibb · collabCommonwealth Foundation for Cancer Research · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goals of this clinical research study are to learn the tolerable and effective doses of the drug MK-0646 that can be given in combination with Sprycel (dasatinib) and Faslodex (fulvestrant) to patients with hormone receptor-positive metastatic breast cancer. The safety of these drugs will be studied as well as markers in the tumors that may help researchers predict the tumors' reaction to the treatment.
Timeline
- Start
- 2009-11
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Comparator | dalotuzumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Comparator | dasatinib anhydrous | Small molecule | 70 mg | Oral |